Capricor Targets Open Label Data to Avoid Rejection of Duchenne Therapy

By Adam Feuerstein · STAT News · 2026-08-20

Capricor Therapeutics is attempting to bypass a likely FDA denial of its Duchenne muscular dystrophy treatment by providing results from an open-label extension. Reporting from STAT News suggests this move follows the failure of a Phase 3 study for the cell therapy known as deram

Capricor Therapeutics is attempting to bypass a likely FDA denial of its Duchenne muscular dystrophy treatment by providing results from an open-label extension. Reporting from STAT News suggests this move follows the failure of a Phase 3 study for the cell therapy known as deram